Company Filing History:
Years Active: 2019
Title: Da Eun Hwang: Innovator in Polypeptide Research
Introduction
Da Eun Hwang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of novel polypeptides. With a total of 2 patents, his work focuses on innovative solutions for treating various diseases.
Latest Patents
Hwang's latest patents include a polypeptide capable of binding to vascular endothelial growth factor (VEGF). This polypeptide is designed to inhibit the activity of VEGF, which is crucial for treating and preventing age-related macular degeneration and cancer. The patent outlines a comprehensive method for producing this polypeptide using recombinant microorganisms, along with a composition for therapeutic use.
Another significant patent involves a polypeptide for binding to complement protein C5a. This invention aims to inhibit the activation of C5a, which plays a role in immune diseases and sepsis. The polypeptide demonstrates a higher affinity for C5a compared to its natural receptor, making it a valuable candidate for developing treatments for related diseases.
Career Highlights
Da Eun Hwang is affiliated with the Korea Advanced Institute of Science and Technology, where he conducts his research. His work has garnered attention for its potential applications in medical science, particularly in the fields of oncology and immunology.
Collaborations
Hwang collaborates with notable colleagues, including Hak-Sung Kim and Jeong Hyun Ryou. Their combined expertise enhances the research efforts and innovation in the field of biotechnology.
Conclusion
Da Eun Hwang's contributions to polypeptide research exemplify the impact of innovative thinking in biotechnology. His patents reflect a commitment to advancing medical treatments and improving patient outcomes.